Latest filing published 18 Jan 2022 for Mirati Therapeutics, Inc..
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Vickie S. Reed: trading record in brief
This profile gathers the share dealings of Vickie S. Reed in Mirati Therapeutics, Inc., where the filings describe the role as senior executive. In total, 9 filings cover trades dated from 6 January 2020 to 18 January 2022.
Sales make up the whole of the open-market record (6 sales, €331k). Besides market trades, the filings include 3 share grants. So far in 2022, the count stands at no purchases and 3 sales.
The record was last updated on 18 January 2022 with an open-market sale (€56k) in Mirati Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Vickie S. Reed
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 5,377 shares0Common StockSEC:0001214659-22-000858:0
- 345 shares@ US$135.941929.5% of flowCommon StockSEC:0001214659-22-000470:0
- 758 shares@ US$147.739570.5% of flowCommon StockSEC:0001214659-22-000417:0
3 of 3 declarations
